Theravance Biopharma, Inc.

9.14 USD
-0.30 (-3.18%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Theravance Biopharma, Inc. stock is up 3.28% since 30 days ago. The next earnings date is May 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 9 March’s closed higher than February. In the last 3 Unusual Options Trades, there were 3 CALLs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
05 Jan 14:55 15 Mar, 2024 10.00 CALL 480 2071
05 Jan 16:07 15 Mar, 2024 10.00 CALL 194 2071
05 Jan 16:09 15 Mar, 2024 10.00 CALL 745 2071

About Theravance Biopharma, Inc.

Theravance Biopharma, Inc. discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD) Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor.